Get the Stockscreener App
28.08
0.55%
0.1137
Moderna Inc stock is traded at $28.08, with a volume of 9.05M.
It is up +0.55% in the last 24 hours and up +14.61% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$27.97
Open:
$27.6
24h Volume:
9.05M
Relative Volume:
0.81
Market Cap:
$10.97B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.2169
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+16.90%
1M Performance:
+14.61%
6M Performance:
-0.05%
1Y Performance:
-38.39%
1-Day Range:
$26.89
$28.52
1-Week Range:
$23.93
$28.52
52-Week Range:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
28.07 | 10.93B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.02 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.95 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
892.06 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
415.25 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
194.38 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna, Pfizer, and BioNTech stock briefly dips on FDA Covid vaccine probe - Investing.com Canada
FDA Probes If Covid Shots Might Be Linked to Deaths of Adults - Bloomberg.com
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy? - Finviz
Global AI Infrastructure Shift Ignites Biotech Growth Phase - Investing News Network
Ossiam Has $3.08 Million Stake in Moderna, Inc. $MRNA - MarketBeat
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna (MRNA) Just Reclaimed the 200-Day Moving Average - Yahoo Finance
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average - Nasdaq
Invesco Ltd. Has $195.92 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Lido Advisors LLC Sells 140,814 Shares of Moderna, Inc. $MRNA - MarketBeat
Federated Hermes Inc. Acquires 2,251,497 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Daily Commercial
How Recent Shifts Are Changing the Narrative for Moderna Stock - Yahoo Finance
58,854 Shares in Moderna, Inc. $MRNA Bought by Quantbot Technologies LP - MarketBeat
Moderna, Inc. $MRNA Stock Position Lessened by New York State Common Retirement Fund - MarketBeat
Behavioral Patterns of MRNA and Institutional Flows - news.stocktradersdaily.com
Moderna, Inc. (MRNA): A Bull Case Theory - MSN
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - Victorville Daily Press
Moderna (NASDAQ:MRNA) Shares Up 6.3%Still a Buy? - MarketBeat
Traders Purchase Large Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Finviz
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - MSN
Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average - Finviz
January 2026 Options Now Available For Moderna (MRNA) - Nasdaq
Skandinaviska Enskilda Banken AB publ Trims Position in Moderna, Inc. $MRNA - MarketBeat
Norges Bank Buys Shares of 3,439,999 Moderna, Inc. $MRNA - MarketBeat
Former FDA commissioners castigate plan to change vaccine approval standards - Seeking Alpha
Moderna to Present at Upcoming Investor Conferences in March 2024 - ACCESS Newswire
Moderna In Crisis? FDA Memo Ties Vaccines To Deaths, Stock Tumbles! - Smartkarma
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Seasonal Vaccines Market Accelerating Growth and Rising Opportunities Through 2035 - GlobeNewswire Inc.
CapEx per share of Moderna, Inc. – DUS:0QF - TradingView
The FDA’s Leaked Covid Memo Is Reckless and Dangerous - Bloomberg.com
Moderna, Inc. $MRNA Shares Sold by Hsbc Holdings PLC - MarketBeat
Goodwin Advises Moderna With Its $1.5 Billion Five-Year Credit Facility From Ares Management - Mondaq
Moderna (MRNA): Reassessing Valuation After FDA Signals Tougher Vaccine Approval Standards - Yahoo Finance
Officer Klinger Acquires 120 Of Moderna Inc [MRNA] - TradingView
Pres Hoge Acquires 336 Of Moderna Inc [MRNA] - TradingView
MVP: Williams & Connolly's David M. Krinsky - Law360
Transcript : Moderna, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 11 - MarketScreener
Moderna (MRNA) Responds to FDA Claims Regarding Vaccine Safety - GuruFocus
Moderna, Inc.: Financial Data Forecasts Estimates and Expectations | 0QF | US60770K1079 - marketscreener.com
Moderna, Inc.: Dividend historical data and projections - marketscreener.com
Prudential Financial Inc. Boosts Stake in Moderna, Inc. $MRNA - MarketBeat
Is Moderna Stock Underperforming the Nasdaq? - Barchart.com
Tougher FDA Rules on Vaccine Approval Might Change the Case for Investing in Moderna (MRNA) - Yahoo Finance
Moderna, Novavax Shares Fall on News FDA Plans to Tighten Vaccine Approvals - The Wall Street Journal
Moderna stock falls after FDA vows to impose new vaccine requirements - The Boston Globe
S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia Partnership - Investopedia
Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10 - Investor's Business Daily
Moderna, Other Pharma Stocks Close Lower After US FDA Reportedly Plans to Toughen Vaccine Approval - marketscreener.com
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):